PMP22 and hereditary neuropathy with liability to pressure palsies: As PMP22 haploinsufficiency and hence under expression is responsible for peripheral neuropathy with liability to pressure palsy (HNPP), the control of the downregulation represents one of the challenges of this gene therapy.